Current Report Filing (8-k)
May 17 2016 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report
(Date of
earliest event reported)
May 13, 2016
INOVIO
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14888
|
|
33-0969592
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania
|
|
19462
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (267) 440-4200
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01
.
|
Entry into a Material Definitive Agreement
.
|
As reported in Item 5.07 of this Form
8-K current report, the stockholders of the Company approved the Companys 2016 Omnibus Incentive Plan at the Companys 2016 Annual Meeting of Stockholders held on May 13, 2016. A description of the Companys 2016 Omnibus
Incentive Plan is included in the Companys proxy statement for its 2016 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on March 25, 2016, which description is incorporated by reference into this Form 8-K
as though fully set forth herein.
Item 5.07
.
|
Submission of Matters to a Vote of Security Holders
.
|
Inovio Pharmaceuticals, Inc. (the
Company) held its 2016 Annual Meeting of Stockholders on May 13, 2016. The following are the voting results for each matter voted upon:
Proposal 1: The election of the following nominees as directors of the Company to serve until the Companys 2017 Annual Meeting of
Stockholders and until their successors are elected.
|
|
|
|
|
|
|
|
|
|
|
|
|
Name of Director Nominee
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Avtar S. Dhillon
|
|
|
19,721,659
|
|
|
|
4,704,564
|
|
|
|
29,257,770
|
|
J. Joseph Kim
|
|
|
24,044,525
|
|
|
|
381,698
|
|
|
|
29,257,770
|
|
Simon X. Benito
|
|
|
22,179,757
|
|
|
|
2,246,466
|
|
|
|
29,257,770
|
|
Ángel Cabrera
|
|
|
23,638,903
|
|
|
|
787,320
|
|
|
|
29,257,770
|
|
Morton Collins
|
|
|
22,645,216
|
|
|
|
1,781,007
|
|
|
|
29,257,770
|
|
Adel A.F. Mahmoud
|
|
|
22,328,083
|
|
|
|
2,098,140
|
|
|
|
29,257,770
|
|
David B. Weiner
|
|
|
24,020,872
|
|
|
|
405,351
|
|
|
|
29,257,770
|
|
Nancy J. Wysenski
|
|
|
22,310,153
|
|
|
|
2,116,070
|
|
|
|
29,257,770
|
|
Proposal 2: The ratification of Ernst & Young LLP as the Companys independent registered public
accounting firm for the year ending December 31, 2016.
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
53,244,131
|
|
260,452
|
|
179,410
|
|
0
|
Proposal 3: The approval of the Companys 2016 Omnibus Incentive Plan.
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
17,586,903
|
|
6,504,824
|
|
334,496
|
|
29,257,770
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INOVIO PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Peter Kies
|
|
|
Peter Kies
|
|
|
Chief Financial Officer
|
Date: May 17, 2016
-3-
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024